Renal cell carcinoma (RCC) is the third most common cancer of the urinary system. There is a pressing need for specific biomarkers for advanced/metastatic RCC to enhance diagnostic accuracy and ...
Adding the VEGF inhibitor ramucirumab (Cyramza) to the EGFR inhibitor osimertinib (Tagrisso) slowed progression of untreated EGFR-positive non-small cell lung cancer (NSCLC) by 9 months compared with ...
Opens in a new tab or window Adding the VEGF inhibitor ramucirumab (Cyramza) to the EGFR inhibitor osimertinib (Tagrisso) slowed progression of untreated EGFR-positive non-small cell lung cancer ...
The work presented will be of interest to cancer biologists and more broadly to those interested in NSCLC translational studies. Non-small cell lung cancer (NSCLC) is the most common subtype of lung ...
Anti-VEGF consists of medicated eye injections that target the underlying causes of wet AMD. This treatment is also sometimes recommended for other retinal conditions, such as macular edema caused ...
TU2218 is a novel oral dual inhibitor targeting TGFR1 and VEGFR2. TGF-ß and VEGF pathways are known to suppress the activity of immune checkpoint inhibitors (ICIs), so TU2218 is expected to improve ...